Alzheimer's & Dementia focuses on "bench-to-bedside" studies, drawn from the many scientific and healthcare disciplines involved in this burgeoning area of research. In addition to peer-reviewed research, the journal presents reviews and expert perspectives from leaders in contributing disciplines, as well as editorials and special issues on topics of interest. Abstracts are available free online at the journal's website, www.alzheimersanddementia.org. Individual subscribers may access the full text of all journal content online, and institutions may access the journal online through ScienceDirect, the leading online platform for libraries.
Highlights of the premiere issue include research linking a diet high in folate to a reduced risk of Alzheimer's disease. In that study, Alzheimer's disease risk was reduced by 55 percent for older adults with a total folate intake at or above the U.S. RDA of 400 micrograms per day. Other studies address potentially new approaches to early identification and treatment of Alzheimer's disease and dementia, including the possible protective effect of treatment for high blood pressure.
Alzheimer's & Dementia will be published quarterly, along with a special supplement containing abstracts of papers from each biannual International Conference on Alzheimer's Disease and Related Disorders. Manuscripts are being accepted now through Elsevier's online submission and editorial system, accessible at http://ees.elsevier.com/adj/.
"It is a privilege to work with the Alzheimer's Association in producing this pioneering journal," comments Cynthia Baudendistel, Executive Publisher of Alzheimer's & Dementia for Elsevier. " Alzheimer's & Dementia will prove a uniquely valuable resource to all professionals in the field - from neurobiologists doing basic science research to physicians and others providing frontline care."
About the Alzheimer's Association
The Alzheimer's Association, the world leader in Alzheimer research and support, is dedicated to finding prevention methods, treatments and an eventual cure for Alzheimer's. For nearly 25 years, the donor-supported, not-for-profit Alzheimer's Association has provided reliable information and care consultation; created supportive services for families; increased funding for dementia research; and influenced public policy changes. The Alzheimer's Association's vision is a world without Alzheimer's and its dual mission is to eliminate Alzheimer's disease through the advancement of research and to enhance care and support for individuals, their families and caregivers. For more information, visit www.alz.org or call 1.800.272.3900.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (ttp://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).